Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: A pre-clinical evaluation

Umesh T. Sankpal, Chris M. Lee, Sarah F. Connelly, Omer Kayaleh, Don Eslin, Robert Sutphin, Steven Goodison, Lina Adwan, Nasser H. Zawia, Lenard M. Lichtenberger, Riyaz Basha

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice.

Original languageEnglish (US)
Pages (from-to)675-686
Number of pages12
JournalCellular Physiology and Biochemistry
Volume32
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Neoplasms
Nude Mice
Hematocrit
Clinical Trials, Phase I
Growth
tolfenamic acid
Neuroblastoma
Pancreatic Neoplasms
Cell Survival
Stomach
Body Weight
Cell Proliferation
Hemorrhage
Liver

Keywords

  • Small molecule
  • Sp1
  • Survivin
  • Tolfenamic acid
  • Toxicity

ASJC Scopus subject areas

  • Physiology

Cite this

Sankpal, U. T., Lee, C. M., Connelly, S. F., Kayaleh, O., Eslin, D., Sutphin, R., ... Basha, R. (2013). Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: A pre-clinical evaluation. Cellular Physiology and Biochemistry, 32(3), 675-686. https://doi.org/10.1159/000354471

Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid : A pre-clinical evaluation. / Sankpal, Umesh T.; Lee, Chris M.; Connelly, Sarah F.; Kayaleh, Omer; Eslin, Don; Sutphin, Robert; Goodison, Steven; Adwan, Lina; Zawia, Nasser H.; Lichtenberger, Lenard M.; Basha, Riyaz.

In: Cellular Physiology and Biochemistry, Vol. 32, No. 3, 01.01.2013, p. 675-686.

Research output: Contribution to journalArticle

Sankpal, UT, Lee, CM, Connelly, SF, Kayaleh, O, Eslin, D, Sutphin, R, Goodison, S, Adwan, L, Zawia, NH, Lichtenberger, LM & Basha, R 2013, 'Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: A pre-clinical evaluation', Cellular Physiology and Biochemistry, vol. 32, no. 3, pp. 675-686. https://doi.org/10.1159/000354471
Sankpal, Umesh T. ; Lee, Chris M. ; Connelly, Sarah F. ; Kayaleh, Omer ; Eslin, Don ; Sutphin, Robert ; Goodison, Steven ; Adwan, Lina ; Zawia, Nasser H. ; Lichtenberger, Lenard M. ; Basha, Riyaz. / Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid : A pre-clinical evaluation. In: Cellular Physiology and Biochemistry. 2013 ; Vol. 32, No. 3. pp. 675-686.
@article{e004deeba6f248e4991824c7064b2b85,
title = "Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: A pre-clinical evaluation",
abstract = "Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice.",
keywords = "Small molecule, Sp1, Survivin, Tolfenamic acid, Toxicity",
author = "Sankpal, {Umesh T.} and Lee, {Chris M.} and Connelly, {Sarah F.} and Omer Kayaleh and Don Eslin and Robert Sutphin and Steven Goodison and Lina Adwan and Zawia, {Nasser H.} and Lichtenberger, {Lenard M.} and Riyaz Basha",
year = "2013",
month = "1",
day = "1",
doi = "10.1159/000354471",
language = "English (US)",
volume = "32",
pages = "675--686",
journal = "Cellular Physiology and Biochemistry",
issn = "1015-8987",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid

T2 - A pre-clinical evaluation

AU - Sankpal, Umesh T.

AU - Lee, Chris M.

AU - Connelly, Sarah F.

AU - Kayaleh, Omer

AU - Eslin, Don

AU - Sutphin, Robert

AU - Goodison, Steven

AU - Adwan, Lina

AU - Zawia, Nasser H.

AU - Lichtenberger, Lenard M.

AU - Basha, Riyaz

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice.

AB - Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice.

KW - Small molecule

KW - Sp1

KW - Survivin

KW - Tolfenamic acid

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84884992707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884992707&partnerID=8YFLogxK

U2 - 10.1159/000354471

DO - 10.1159/000354471

M3 - Article

C2 - 24030139

AN - SCOPUS:84884992707

VL - 32

SP - 675

EP - 686

JO - Cellular Physiology and Biochemistry

JF - Cellular Physiology and Biochemistry

SN - 1015-8987

IS - 3

ER -